Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Lung Cancer
Study Summary
This trial is testing a combination of antibodies and T cells to treat lung cancer. It will look at how much of the treatment is safe and what dosage is the most effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organs are functioning well.I am taking less than 10 mg of prednisone daily or its equivalent.I am resistant to platinum-based cancer treatment and have been treated with a PD1/PDL1 inhibitor. I am currently on low-dose steroids or none at all.I have cancer that did not respond to platinum-based treatment and have been treated with a PD1/PDL1 inhibitor.My organs are functioning well.You have a life expectancy of ≥ 12 weeks.\nI am a woman who can have children and have a negative pregnancy test taken within the last 3 days.You are expected to live for less than 12 weeks.My organs are not functioning properly.I am a woman who can have children and have had a negative pregnancy test in the last 3 days.I have not had platinum-based chemotherapy.I have cancer that didn't respond to platinum-based treatment and have been treated with a PD1/PDL1 inhibitor.
- Group 1: iC9.GD2.CAR.IL-15 T Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the fundamental aim of this clinical study?
"This medical trial is assessing cytokine release syndrome (CRS) for a time frame of up to 4 weeks. Secondary outcomes in this study include disialoganglioside expression, overall response rate and duration of response which will be measured using immunohistochemistry on tumor samples collected from participants according to Response Evaluation Criteria In Solid Tumors criteria. ORR is calculated by summing the number of patients that achieved complete or partial responses divided by the total number who received treatment while DOR is noted as starting with either partial or full respose to disease progression based on RECIST 1.1 metrics: CR defined as disappearance"
Are patients being recruited for this experiment currently?
"According to clinicaltrials.gov, this medical experiment is no longer enrolling candidates. It was initially listed on January 15th 2023 and its most recent update occurred in November 16th 2022. Nevertheless, 1979 other trials are actively recruiting patients at the present time."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger